The clinical and pathologic spectrum of recurrent carotid stenosis

Background Hemodynamically significant (≥50%) carotid restenosis occurs in approximately 10% to 12% of individuals undergoing carotid endarterectomy. The underlying pathology is usually neointimal thickening within 3 years and recurrent atherosclerosis thereafter. Although a number of etiologic factors have been implicated in the development of restenosis, the etiology remains unclear and preventative measures relatively ineffective. Methods A review of the English literature was undertaken to determine the incidence, clinical presentation, and pathologic features of carotid restenosis. Conclusions Carotid restenosis is the major factor limiting long-term patency after carotid endarterectomy. Although drug therapy has been shown to be effective in preventing restenosis in animal models, the results of clinical human trials have been disappointing. Delineation of the biochemical and molecular mechanisms contributing to the development of restenosis is essential if effective therapeutic interventions are to be developed.